Tyler Hulett

Tyler Hulett, PhD, is Chief Scientific Officer of CDI Laboratories, where he builds and oversees antibody discovery platform technologies for the Cancer Grand Challenges ATLAS team. One of these platforms is HuProt, the world's most complete synthetic human proteome – featuring over 21,000 unique full-length human proteins on a microarray. HuProt enables unbiased autoantibody discovery from serum samples. Tyler's team has also pioneered the first commercial deployment of Phage-Display Immunoprecipitation Sequencing (PhIP-Seq), a programmable technology that identifies antibody targets at epitope-level resolution across chosen proteomes – viral (VirScan), tumour, microbial, allergens, and more.  

CDI's platforms have become foundational tools for autoantibody biomarker discovery in oncology, autoimmunity, and neurodegeneration. Since joining CDI in 2019, Tyler has led the creation of data pipelines and quality control for these technologies, personally analysing hundreds of studies for academic and pharmaceutical partners worldwide. Together, these platforms have powered over 400 peer-reviewed publications. He trained in cancer immunotherapy under Bernard A. Fox at the Earle A. Chiles Research Institute while a doctoral student at Oregon Health & Science University.